PTPRC and uterine cervix carcinoma in situ: Immune cells, identified by CD45 expression, were significantly elevated in treated cancer samples compared to normal (p ≤ 0.001), inflammatory (p ≤ 0.001), CIN I (p ≤ 0.01), and CIN III (p ≤ 0.01) tissues (Figure 5C).